MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
series b redeemable...
$200,000K
Exercise of options into
common stock
$1,033K
Net cash provided by
(used in) financing...
$185,826K
Canceled cashflow
$15,207K
Net increase
(decrease) in cash and cash...
$143,657K
Canceled cashflow
$42,169K
Issuance costs from the
private placement...
$15,145K
Principal payments for
financing leases
$62K
Net cash assumed in
the acquisition of...
-$6,464K
Maturities of short-term
investments
$6,000K
Acquired in-process
research and development...
-$132,957K
Stock-based compensation
expense
$12,898K
Prepaid expenses
-$10,744K
Compensation and employee
benefits
$2,645K
Other assets
-$442K
Non-cash lease expense
$381K
Depreciation and
amortization
$29K
Amortization of financing
lease right-of-use...
$1K
Net cash (used in)
provided by investing...
-$31,436K
Net cash used in
operating activities
-$10,733K
Canceled cashflow
$12,464K
Canceled cashflow
$160,097K
Purchases of short-term
investments
$43,894K
Net loss
-$170,236K
Purchases of property and
equipment
$6K
Operating lease
liabilities
-$407K
Accounts payable and
accrued liabilities
-$104K
Accretion on marketable
securities
-$83K
Back
Back
Cash Flow
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)
source: myfinsight.com